Intercell Executes Multi-Year Contract for Supply of IXIARO to the United States Military
First sales of IXIARO under this military contract expected soon
Advertisement
Intercell AG announced that the Company has successfully entered into a multi-year contract with the Defense logistics Agency (DLA), Defense Supply Center of the U.S. Department of Defense to supply IXIARO, a vaccine against Japanese encephalitis (JE). The first sales of IXIARO under this contract are expected in the near future.
This supply contract was negotiated in response to a Request for Proposals (RFP) issued by the DLA in August 2008. The parties were able to move forward to finalize the contract after IXIARO was approved by the Food and Drug Administration on March 30. The major terms of this contract are as follows:
- Exclusive contract for Intercell to supply DLA with all their requirements for JE vaccine
- Five-year contract, with annual options for price modifications
IXIARO was developed by Intercell under an agreement with the Walter Reed Army Institute of Research (WRAIR).
Intercell will directly distribute and market IXIARO to the U.S. military. Novartis Vaccines USA will market and distribute the vaccine to the private market in the U.S.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Independent research teams identify first infectious agent associated with colon cancer
Epigenomics AG: Full Year Results for the Year Ended 31 December 2010 - Focus 2010/2011 on U.S. product development and FDA submission
Renal reabsorption in living devices - 3D bioprinted, vascularized proximal tubules mimic the human kidney's reabsorption functions